GlaxoSmithKline: Pulmonary Disease, Chronic Obstructive trials

The registry lists 276 Pulmonary Disease, Chronic Obstructive studies with GlaxoSmithKline as lead sponsor. 7 are open to participants now and 141 have results posted.

Phase 1 84Phase 2 47Phase 3 65Phase 4 38No phase 43(a study in two phases counts in both)

Studies

Page 2 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01372410Phase 2Results posted
• Infectious Pathogens in Acute Respiratory Illness in Adults and ElderlyCompletedNCT01360398Not applicableResults posted
• A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))CompletedNCT01342913Phase 3Results posted
• Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety PopulationCompletedNCT01337336Results posted
• A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPDCompletedNCT01336608Phase 3Results posted
• Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance TherapiesCompletedNCT01332461Results posted
• Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01331694Results posted
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study ACompletedNCT01328444Phase 3Results posted
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study BCompletedNCT01323660Phase 3Results posted
• Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01323634Phase 3Results posted
• Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01323621Phase 3Results posted
• 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseCompletedNCT01316913Phase 3Results posted
• 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseCompletedNCT01316900Phase 3Results posted
• A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01316887Phase 3Results posted
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01313676Phase 3Results posted
• A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPDCompletedNCT01313650Phase 3Results posted
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPDCompletedNCT01313637Phase 3Results posted
• Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01218126Phase 2Results posted
• A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPDCompletedNCT01192191Phase 3Results posted
• Prophylactic Efficacy of Relenza Against Influenza A and BCompletedNCT01156701Results posted
• Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01124422Phase 4Results posted
• Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization StudyCompletedNCT01110200Phase 4Results posted
• A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to PlaceboCompletedNCT01072149Phase 3Results posted
• Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01054885Phase 3Results posted
• A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01053988Phase 3Results posted
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPDCompletedNCT01039675Phase 2Results posted
• 28-day Repeat Dose Study of GSK573719CompletedNCT01030965Phase 2Results posted
• A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01017952Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01009463Phase 3Results posted
• Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00984659Phase 4Results posted
• GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary DiseaseCompletedNCT00950807Phase 2Results posted
• A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00857766Phase 4Results posted
• Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator MonotherapyCompletedNCT00791518Results posted
• A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT00784550Phase 4Results posted
• Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPDCompletedNCT00749411Phase 2Results posted
• A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 DaysCompletedNCT00732472Phase 2Results posted
• A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00731822Phase 2Results posted
• Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00676052Phase 2Results posted
• Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)CompletedNCT00633217Phase 4Results posted
• A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00606684Phase 2Results posted
• Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IVCompletedNCT00527826Phase 4Results posted
• A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.CompletedNCT00519376Phase 2Results posted
• Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00515502Phase 2Results posted
• A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.CompletedNCT00453479Phase 2Results posted
• Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of BreathCompletedNCT00442468Results posted
• A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00372112Phase 2Results posted
• Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.CompletedNCT00355342Phase 4Results posted
• GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)CompletedNCT00269087Phase 3Results posted
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European AncestryCompletedNCT06979518Phase 1
• A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy ParticipantsCompletedNCT06597500Phase 1
• Retrospective Analysis of Systemic Glucocorticoid Mediated Long-term Effects, Patient Pathways and Economic Burden Across Multiple IndicationsCompletedNCT06488703
• A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseActive, not recruitingNCT06154837Phase 1
• Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild AsthmaCompletedNCT05398198Phase 1
• Etiology of Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) in JapanCompletedNCT03957577
• Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness StudyWithdrawnNCT03949842Phase 4
• Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in Routine Practice and Their Impact on Treatment DecisionsCompletedNCT03465332
• Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03436511
• The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on AsthmaWithdrawnNCT03363191Phase 4
• Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) PatientsTerminatedNCT03243760Phase 1
• RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)CompletedNCT03219255
• Patient Characteristics and Treatment Modalities in COPD Patients in ChinaCompletedNCT03161587
• The Extended Salford Lung Study ("Ex-SLS") Data Access ProjectCompletedNCT03152669
• FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference SurveyCompletedNCT03046069
• A Cross-sectional Study on COPD PrevalenceCompletedNCT03028207
• Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and Eosinophilia Among Primary Care PatientsCompletedNCT03018808
• Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy SubjectsCompletedNCT02972905Phase 1
• A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese SubjectsCompletedNCT02837380Phase 1
• A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)WithdrawnNCT02731846Phase 3
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy SubjectsCompletedNCT02691325Phase 1
• GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)CompletedNCT02666287Phase 1
• Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & AsthmaCompletedNCT02619357Phase 1
• Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT02551614Phase 1
• A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With OmeprazoleCompletedNCT02453022Phase 1
• Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02302417Phase 2
• To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic ConditionsCompletedNCT02262689Phase 1
• GSK2190915A - Bioavailability StudyCompletedNCT02224521Phase 1
• Helium-3 MRI Imaging Study in COPDCompletedNCT02207452Phase 1
• Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles ComparisonCompletedNCT02076269Phase 1
• Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in CombinationCompletedNCT02064504Phase 1
• A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly SubjectsCompletedNCT02006537Phase 1
• Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.CompletedNCT01984086Phase 1
• Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.CompletedNCT01899638Phase 1
• Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different DosesCompletedNCT01894386Phase 1
• ROTAHALER Device Optimization StudyCompletedNCT01890863Phase 1
• WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) SubjectsCompletedNCT01763463
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy SubjectsCompletedNCT01762878Phase 1
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese SmokersCompletedNCT01762774Phase 1
• A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy SubjectsCompletedNCT01691547Phase 1
• WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial InfarctionCompletedNCT01636726
• Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid PopulationCompletedNCT01615783
• A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy VolunteersCompletedNCT01577680Phase 1
• Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal ImpairmentCompletedNCT01571999Phase 1
• A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate/SalmeterolCompletedNCT01540708Phase 1
• Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.CompletedNCT01521390Phase 1
• QTc Study GSK573719+GW642444CompletedNCT01521377Phase 1
• Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary CareCompletedNCT01516528
• Airflow Limitation in Cardiac Diseases in EuropeCompletedNCT01485159
• A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is ReducedCompletedNCT01453478Phase 1
• An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy VolunteersCompletedNCT01449799Phase 1
• Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease ExacerbationCompletedNCT01431911